Sucampo Pharmaceuticals Company Profile (NASDAQ:SCMP)

Sucampo Pharmaceuticals trades on the NASDAQ under the ticker symbol "SCMP."

Sucampo Pharmaceuticals, Inc. (NASDAQ:SCMP) released its quarterly earnings data on Wednesday, May, 3rd. The company reported $0.23 earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.28 by $0.05. The company had revenue of $56.30 million for the quarter, compared to the consensus estimate of $54.15 million. Sucampo Pharmaceuticals had a return on equity of 43.27% and a net margin of 11.36%. Sucampo Pharmaceuticals's revenue for the quarter was up 19.3% compared to the same quarter last year. During the same period last year, the company earned $0.21 EPS. View Sucampo Pharmaceuticals' Earnings History.

Sucampo Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, August, 1st 2017. View Earnings Estimates for Sucampo Pharmaceuticals.

6 brokerages have issued 1-year price objectives for Sucampo Pharmaceuticals' shares. Their predictions range from $11.00 to $27.00. On average, they expect Sucampo Pharmaceuticals' stock price to reach $17.17 in the next year. View Analyst Ratings for Sucampo Pharmaceuticals.

Here are some recent quotes from research analysts about Sucampo Pharmaceuticals stock:

• 1. According to Zacks Investment Research, "Sucampo is focused on expanding its sole marketed product, Amitiza’s label and penetrating into new markets. Moreover, the company’s collaborations with firms like Takeda and Mylan for the commercialization of Amitiza is a big positive. In addition, through the agreement with Cancer Prevention Pharmaceuticals, the company acquired an exclusive option to develop and commercialize its combination, CPP-1X/sulindac, in North America. Moreover, with acquisition of Vtesse, Sucampo added a late stage program in Niemann-Pick Disease type C1 to its pipeline. However, Sucampo’s dependence on Amitiza for growth is concerning. Also, some companies are trying to market and sell generic version of Amitiza. Any decline in Amitiza's sales will adversely impact the top-line. Moreover, it is no stranger to pipeline setbacks. The company has lowered its earnings guidance to incorporate the Vtesee acquisition." (7/4/2017)
• 2. Maxim Group analysts commented, "Sucampo has acquired privately owned Vtesse Inc. and its lead orphan drug candidate for Niemann-Pick Type C1, VTS-270, for $170M in cash & the rest in stock: total of $200M. There is also a contingent earn-out (payments in the mid-single digit to double-digit royalties on global net sales) of the product at increasing net sales levels." (4/3/2017)
• 3. Jefferies Group LLC analysts commented, "Post the Q4 results and guidance we have revisited our assumptions and are making two changes to our model reflecting ' 1) likely Amitiza mandated price erosion in Japan and 2) our switch projections for the alternative formulation of Amitiza. We also fine-tune our FY17 revs and EPS estimates. We continue to view potential business development/M&A as critical to the longer term outlook given the finite life of Amitiza and await mgt's plans." (3/17/2017)
• 4. Mizuho analysts commented, "We reiterate our Buy rating and $16 PT into the 4Q:16 print on March 8. The near-term Amitiza outlook remains favorable in both the U.S. and Japanese markets, which we believe may support additional optionality for the company in front of its 2021 patent cliff." (3/6/2017)

Some companies that are related to Sucampo Pharmaceuticals include Synergy Pharmaceuticals (SGYP), Acorda Therapeutics (ACOR), Aduro Biotech (ADRO), Omeros Corporation (OMER), Achaogen (AKAO), Ascendis Pharma A/S (ASND), Insys Therapeutics (INSY), Five Prime Therapeutics (FPRX), NeuroDerm (NDRM), PTC Therapeutics (PTCT), Epizyme (EPZM), ZIOPHARM Oncology (ZIOP), Keryx Biopharmaceuticals (KERX), Aclaris Therapeutics (ACRS), Retrophin (RTRX), Flexion Therapeutics (FLXN), La Jolla Pharmaceutical Company (LJPC) and Vanda Pharmaceuticals (VNDA).

Sucampo Pharmaceuticals' management team includes the folowing people:

• Peter S. Greenleaf, Chairman of the Board, Chief Executive Officer
• Peter P. Pfreundschuh CPA, Chief Financial Officer, Principal Financial Officer
• Matthias Alder, Executive Vice President
• Max Donley, Executive Vice President of Human Resources
• Thomas J. Knapp, Executive Vice President, Chief Legal Officer and Corporate Secretary
• Stanley G. Miele, Senior Vice President - Sales and Marketing; President of Sucampo Pharma Americas, LLC
• Peter A. Kiener Ph.D., Chief Scientific Officer
• Alex Driggs, Acting General Counsel, Corporate Secretary
• Peter Lichtlen M.D., Ph.D., Chief Medical Officer
• John H. Johnson, Lead Independent Director

Sucampo Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Malaga Cove Capital LLC (0.18%), Eqis Capital Management Inc. (0.07%), Bank of Montreal Can (0.04%), Capstone Asset Management Co. (0.03%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Sucampo Pharmaceuticals stock include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf. View Institutional Ownership Trends for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including Eqis Capital Management Inc., Bank of Montreal Can and Malaga Cove Capital LLC. Company insiders that have sold Sucampo Pharmaceuticals stock in the last year include Andrew P Smith, Daniel P Getman, Matthias Alder and Peter Greenleaf. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Sucampo Pharmaceuticals' stock was bought by a variety of institutional investors in the last quarter, including Capstone Asset Management Co. and Louisiana State Employees Retirement System. View Insider Buying and Selling for Sucampo Pharmaceuticals.

Shares of Sucampo Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of Sucampo Pharmaceuticals stock can currently be purchased for approximately $10.90.